Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $806M. The Maz Rating grades it against the other companies in its sector.
Ironwood Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.87, Ironwood Pharmaceuticals, Inc. trades at 5.3x trailing earnings and 2.0x sales, with an EV/EBITDA of 2.8. Over the last twelve months it generated about $404M of revenue and $151M of net income. It runs a gross margin of 99.9%, an operating margin of 62.8% and a net margin of 37.4%. It shows return on equity of -93.4%, return on invested capital of 64.0% and a free cash flow yield of 25.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 6.51. Over the past 52 weeks the share price ranged from $2.95 to $5.78, with a beta of 0.24.
Ironwood Pharmaceuticals, Inc. does not currently pay a dividend.
30 Wall Street analyst ratings cover the stock: 11 Buy, 16 Hold and 3 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Ironwood Pharmaceuticals, Inc. (IRWD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.9% / 30% · Interest income / Revenue 0.47% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.9% / 33% · Receivables / Mkt Cap (36m) 19.7% / 49% · Interest income / Revenue 0.47% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.9% / 33.33% · Receivables / Mkt Cap (24m) 19.7% / 33.33% · Interest income / Revenue 0.47% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 110.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 42.7% / 33.33% · Receivables / Avg Assets (4Q) 28.3% / 33.33% · Interest income / Revenue 0.47% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 29.7% / 33.33% · (Cash+Recv) / Total Assets 75.4% / 33.33% · Interest income / Revenue 0.47% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Ironwood Pharmaceuticals, Inc. (IRWD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Ironwood Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.47% of each dividend: Ironwood Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.